• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TWST

    Twist Bioscience Corporation

    Subscribe to $TWST
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.

    IPO Year: 2018

    Exchange: NASDAQ

    Website: twistbioscience.com

    Peers

    $ILMN

    Recent Analyst Ratings for Twist Bioscience Corporation

    DatePrice TargetRatingAnalyst
    12/13/2024$60.00Outperform
    Wolfe Research
    6/4/2024$53.00Buy
    Guggenheim
    1/17/2024$25.00 → $45.00Neutral → Buy
    Goldman
    9/27/2023$27.00Buy
    Berenberg
    1/5/2023$33.00Sector Outperform
    Scotiabank
    1/3/2023$28.00 → $36.00In-line → Outperform
    Evercore ISI
    3/2/2022Outperform
    Cowen
    2/7/2022$130.00 → $75.00Overweight
    Barclays
    2/7/2022$110.00 → $70.00Market Perform
    SVB Leerink
    10/15/2021Outperform
    Cowen
    See more ratings

    Twist Bioscience Corporation FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

      For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

      3/26/21 3:51:09 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Twist Bioscience Corporation SEC Filings

    See more
    • SEC Form 144 filed by Twist Bioscience Corporation

      144 - Twist Bioscience Corp (0001581280) (Subject)

      6/6/25 3:28:55 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Twist Bioscience Corporation

      10-Q - Twist Bioscience Corp (0001581280) (Filer)

      5/5/25 4:05:23 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Twist Bioscience Corp (0001581280) (Filer)

      5/5/25 7:27:31 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

      SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      4/17/25 9:35:32 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Twist Bioscience Corporation

      144 - Twist Bioscience Corp (0001581280) (Subject)

      2/21/25 3:13:04 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Twist Bioscience Corporation

      S-8 - Twist Bioscience Corp (0001581280) (Filer)

      2/12/25 4:37:31 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

      SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)

      2/12/25 4:35:31 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Twist Bioscience Corp (0001581280) (Filer)

      2/11/25 5:00:21 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Twist Bioscience Corporation

      SCHEDULE 13G - Twist Bioscience Corp (0001581280) (Subject)

      2/5/25 7:48:59 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Twist Bioscience Corporation

      10-Q - Twist Bioscience Corp (0001581280) (Filer)

      2/3/25 4:09:45 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Twist Bioscience Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Cho Dennis sold $3,147 worth of shares (94 units at $33.48), decreasing direct ownership by 0.09% to 104,967 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      6/18/25 4:05:11 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP of Human Resources Green Paula sold $27,083 worth of shares (853 units at $31.75), decreasing direct ownership by 0.66% to 127,895 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      6/10/25 4:05:15 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Cho Dennis sold $8,160 worth of shares (257 units at $31.75), decreasing direct ownership by 0.24% to 105,061 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      6/10/25 4:05:16 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Accounting Officer Werner Robert F. sold $7,144 worth of shares (225 units at $31.75), decreasing direct ownership by 0.45% to 49,966 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      6/10/25 4:05:09 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Leproust Emily M. sold $68,898 worth of shares (2,170 units at $31.75), decreasing direct ownership by 0.33% to 647,460 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      6/10/25 4:05:10 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Accounting Officer Werner Robert F. sold $23,264 worth of shares (839 units at $27.73), decreasing direct ownership by 2% to 50,191 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/28/25 4:05:09 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Leproust Emily M. sold $83,351 worth of shares (2,802 units at $29.75), decreasing direct ownership by 0.43% to 649,630 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/23/25 4:05:16 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP of Human Resources Green Paula sold $18,800 worth of shares (632 units at $29.75), decreasing direct ownership by 0.49% to 128,748 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/23/25 4:05:19 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Accounting Officer Werner Robert F. sold $7,199 worth of shares (242 units at $29.75), decreasing direct ownership by 0.47% to 51,030 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/23/25 4:05:15 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and COO Finn Patrick John sold $55,835 worth of shares (1,877 units at $29.75), decreasing direct ownership by 0.77% to 240,783 units (SEC Form 4)

      4 - Twist Bioscience Corp (0001581280) (Issuer)

      5/23/25 4:05:18 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Twist Bioscience Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions

      Offer end-to-end workflow from library prep through sequencing Twist to be sole provider of new Trinity™ library prep and target enrichment kits for Element AVITI™ sequencer Joint commercial activities to expand customer access to new NGS tools Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element's AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows. This press release features multi

      5/22/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events. About Twist Bioscience Corporation At Twist Bios

      5/15/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 72,991 equity awards, consisting of 53,600 restricted stock units ("RSUs") and up to 19,379 performance stock units ("PSUs"), to 36 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan and related form of restricted stock unit award agreement in accor

      5/13/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience and Ginkgo Bioworks Revise Collaboration

      New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508352416/en/ Under the terms of the revised three-year $15

      5/8/25 8:00:00 AM ET
      $DNA
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal second quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its f

      5/5/25 7:15:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Spins Out DNA Data Storage as Independent Company

      Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital Partners, Earth Foundry, Rsquared VC, In-Q-Tel (IQT), and other undisclosed investors Varun Mehta, previously founder of Nimble Storage, to serve as CEO of Atlas Data Storage Twist remains focused on serving customers across the life sciences spectrum and expanding rev

      5/5/25 7:10:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System

      Adds to robust offering of NGS tools enabling exome sequencing, whole genome sequencing, RNA sequencing, deep sequencing for liquid biopsy research and MRD, and methylation detection Diverse portfolio of adapter sets now includes industry leading number of unique indexes at 3,072 HT UDI Adapters Enables multiplexing and high throughput sequencing Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced the expanded launch of the Twist High Throughput (HT) Unique Dual Index (UDI) Adapter System to enable multiplexing and sample batching at scale. Indexing is a critical part of the li

      4/24/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience to Report Fiscal 2025 Second Quarter Financial Results on Monday, May 5, 2025

      Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, before the opening of the market on May 5, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor

      4/14/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics

      Collaboration to enable cost-effective end-to-end genotyping across large animal and plant populations Companies to present poster at AGBT-Ag Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today announced a collaboration to accelerate the adoption of NGS workflows in agricultural genomics (agrigenomics) by offering Twist's FlexPrep™ Ultra-High Throughput (UHT) Library Preparation Kit with Curio's bioinformatics software and data platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/

      3/31/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost

      — Supports Acceleration of Research Across Multiple Industries; Maximizes Budget — Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnaround time. "At Twist, we recognize the increasing challenge within colleges, universities and research institutions to securing research funding and appreciate that scientific progress must continue unhindered, as Science Doesn't Stop," said Emily M. Leproust, Ph.D.,

      3/11/25 7:30:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care